GlobeNewswire by notified

Scandinavian Tobacco Group A/S: Transactions in connection with share buy-back programme

Share
Company Announcement
No. 55/2022

Copenhagen, 5 Sep 2022


Transactions in connection with share buy-back programme

On 19 May 2022, Scandinavian Tobacco Group A/S announced that the share buy-back programme that was initiated 9 March 2022 was increased to an aggregated value of up to DKK 1,000 million. The purpose of the programme is to adjust the Company’s capital structure and meet obligations relating to the Group’s share-based incentive programme.

Part of the buy-back programme is executed in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (the “Market Abuse Regulation”) and Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour rules. Another part of the share buy-back programme is conducted as a directed buy-back from Chr. Augustinus Fabrikker Aktieselskab and C.W. Obel A/S as further described in company announcement no. 35/2022. The share buy-back programme will end no later than 28 February 2023.

The following transactions have been executed from 29 August to 2 September 2022:

Number of sharesAverage
purchase price, DKK
Transaction value, DKK
Accumulated, last announcement2,424,525343,506,426
29-Aug-2228,361 111.13 3,151,744
30-Aug-22 22,680  112.65  2,555,004
31-Aug-22 30,000  111.26  3,337,707
01-Sep-22 30,260  110.67 3,348,929
02-Sep-22 25,672  109.10  2,800,915
Total, 29 August- 2 September 2022136,973  110.9315,194,299
Bought from CAF, 2 September 2022*61,128 110.936,780,877
Bought from CWO, 2 September 2022* 28,300 110.93 3,139,295
Accumulated under the programme2,650,926368,620,897

*According to separate agreements as from 20 May 2022 Chr. Augustinus Fabrikker Aktieselskab (CAF) participates on a 27.0% pro-rata basis and C.W.Obel A/S (CWO) participates on a 12.5% pro-rata basis to the shares purchased in the share buy-back programme.

A detailed overview of transactions during the period 29 August –2 September 2022 is attached to this announcement.

Following the above transactions Scandinavian Tobacco Group A/S owns a total of 3,096,988 treasury shares, corresponding to 3.33% of the total share capital.

For further information, please contact:
Torben Sand, Head of Investor Relations,
phone: +45 5084 7222 or torben.sand@st-group.com

Attachments

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Zoltek celebrates the founder’s 80th birthday6.12.2022 20:05:26 CET | Press release

Leading the carbon fiber industry on a global scale St. Louis, Missouri, USA, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Zoltek Corporation, the largest global manufacturer of industrial grade carbon fiber, has recently celebrated the 80th birthday of its founder, Zsolt Rumy. Born in December 1942 in Budapest, Hungary, Mr. Rumy was a carbon fiber industry pioneer that ultimately changed the carbon fiber world. He created the first industrial-grade carbon fiber made to compete against other common building materials, and created Zoltek Corporation to drive the commercialization of carbon fibers. Mr. Rumy fled Soviet communism after the Hungarian Revolution in 1956, and arrived in the US as a 14-year old war refugee through the International Red Cross and Catholic Charities. He later graduated with a chemical engineering degree from the University of Minnesota, accepted a position with Monsanto Company and moved to St. Louis, Missouri in 1966. After several years of corporate sales and engineerin

Mandalay Resources Corporation tillkännager CEO-förändring och befordringar i ledningsgruppen6.12.2022 19:30:23 CET | Pressemelding

TORONTO, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Mandalay Resources Corporation (”Mandalay” eller ”bolaget”) (TSX: MND, OTCQB: MNDJF) tillkännagav idag att Dominic Duffy har informerat styrelsen om sitt beslut att avgå som President och Chief Executive Officer av personliga skäl. Dominic Duffy kommer att fortsätta som CEO och hjälpa till med ledarskapsövergången fram till sin avgång i juli 2023. Han kommer också att kvarstå i styrelsen i en icke-verkställande roll efter sin avgång som CEO. Mandalays styrelse har anlitat ett rekryteringsföretag för att hitta en efterträdare till Dominic Duffy. Mandalay har även nöjet att meddela att Ryan Austerberry från och med den 15 december 2022 befordras till Chief Operating Officer. Ryan Austerberry är för närvarande General Manager vid Mandalays Costerfield-gruva och var tidigare General Manager för Mandalays andra verksamma gruva, Björkdal. Adam Self, nuvarande Mine Manager på Costerfield, ersätter Ryan Austerberry som Costerfields General Manager. Br

Novartis Kisqali® prolonged PFS benefit for pre- and perimenopausal patients with aggressive HR+/HER2− metastatic breast cancer compared to chemotherapy6.12.2022 19:30:00 CET | Press release

RIGHT Choice Phase II trial is the first randomized study in patients with aggressive HR+/HER2− metastatic breast cancer (MBC), including visceral crisis, comparing a CDK4/6 inhibitor (CDK4/6i) plus endocrine therapy (ET) versus combination chemotherapy (CT)1 Kisqali plus ET demonstrated a statistically significant progression-free survival (PFS) benefit of one year compared to combination CT; data to be presented at SABCS 20221 Kisqali is a unique CDK4/6i that has consistently shown statistically significant overall survival benefit while preserving or improving quality of life across three Phase III trials in MBC, including in patients with aggressive disease1,2-13 Basel, December 6, 2022 — Novartis today announced results from the RIGHT Choice Phase II trial evaluating Kisqali® (ribociclib) plus endocrine therapy (ET) against combination chemotherapy (CT) in the first-line setting for pre- and perimenopausal patients with aggressive forms of hormone receptor-positive, human epiderma

Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA6.12.2022 19:00:00 CET | Press release

Negma Group has converted 80convertible bonds in Oxurion resulting in a EUR 200,000capital increase. This is part of Negma Group’s EUR 30 million Capital Commitment1 that will allow Oxurion to focus on progressing its novel and differentiated back of the eye drug candidate targeting potential market opportunities of over USD 5billion. Leuven, BELGIUM,Boston, MA, US–December6, 2022– 07.00 PM CET – In accordance with article 15 of the Belgian Act of May 2, 2007 on the disclosure of major participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions, Oxurion NV (Euronext Brussels: OXUR) (the “Company” or “Oxurion”), announces the below information, following the issuance of 21,008,403 new ordinary shares on December 5, 2022, for a total amount of EUR 200,000, as the result of the conversion of 80 class B convertible bonds, pursuant to the Capital Commitment entered into with Negma Group. Following completion of the capital i

Yara approves dividend of NOK 10 per share6.12.2022 18:48:00 CET | Press release

Oslo, 6December 2022:The Yara International ASA Extraordinary General Meeting today approved a dividend of NOK 10.00 per share in line with the Board’s proposal. The dividend of NOK 10.00 per share will be paid on 15 December 2022 to shareholders as of 6 December 2022 (registered in VPS as of 8 December 2022), and the Yara share will be traded ex-dividend from 7 December 2022. American Depository Receipts (ADRs) will also be traded ex-dividend from 7 December 2022, with a dividend payment date of 22 December 2022. The full minutes of the Extraordinary General Meeting are available on Yara’s website: Reports and presentations | Yara International Contact Anika Jovik, Head of Investor Relations Mobile: (+47) 472 24 959 E-mail: anika.jovik@yara.com About Yara Yara grows knowledge to responsibly feed the world and protect the planet. Supporting our vision of a world without hunger and a planet respected, we pursue a strategy of sustainable value growth, promoting climate-friendly crop nutr